{
    "organizations": [],
    "uuid": "922b05597493ed49389fd9783ca7f22bc328074e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-adamis-pharmaceuticals-announces-f/brief-adamis-pharmaceuticals-announces-fda-acceptance-for-review-for-the-supplemental-new-drug-application-idUSASB0C57Q",
    "ord_in_thread": 0,
    "title": "BRIEF-Adamis Pharmaceuticals Announces FDA Acceptance For Review For The Supplemental New Drug Application",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 12, 2018 / 2:08 PM / Updated 12 minutes ago BRIEF-Adamis Pharmaceuticals Announces FDA Acceptance For Review For The Supplemental New Drug Application Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Adamis Pharmaceuticals Corp: \n* ADAMIS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR REVIEW FOR THE SUPPLEMENTAL NEW DRUG APPLICATION OF ITS LOW DOSE SYMJEPI PRODUCT CANDIDATE \n* ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED \n* ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED \n* ADAMIS PHARMACEUTICALS CORP - FDA INDICATED IF NO MAJOR DEFICIENCIES IDENTIFIED, THEY ARE TARGETING SEPTEMBER 3, 2018 TO COMMUNICATE PROPOSED LABELING Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)",
    "published": "2018-02-12T16:08:00.000+02:00",
    "crawled": "2018-02-12T16:22:34.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "pharmaceutical",
        "announces",
        "fda",
        "acceptance",
        "review",
        "supplemental",
        "new",
        "drug",
        "application",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "adamis",
        "pharmaceutical",
        "corp",
        "adamis",
        "pharmaceutical",
        "announces",
        "fda",
        "acceptance",
        "review",
        "supplemental",
        "new",
        "drug",
        "application",
        "low",
        "dose",
        "symjepi",
        "product",
        "candidate",
        "adamis",
        "pharmaceutical",
        "corp",
        "fda",
        "indicated",
        "potential",
        "review",
        "issue",
        "identified",
        "adamis",
        "pharmaceutical",
        "corp",
        "fda",
        "indicated",
        "potential",
        "review",
        "issue",
        "identified",
        "adamis",
        "pharmaceutical",
        "corp",
        "fda",
        "indicated",
        "major",
        "deficiency",
        "identified",
        "targeting",
        "september",
        "communicate",
        "proposed",
        "labeling",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}